Drugs / SXRN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06736275 | Sep 2024 → Oct 2027 expected | cancer of unknown primary site, hypoproteinemia, hypercatabolic | Jiangsu Nutai Biologics Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SXRN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06736275 ↗ |
| Modality | Other / unclassified | “SXRN is a naked plasmid DNA drug targeting miRNA.” NCT06736275 ↗ |
| Route | Intravenous | “patients receive 4 mg SXRN injection, intravenous infusion, once daily for 14 consecutive days” NCT06736275 ↗ |